Trial Profile

A Randomized, Double Blind, Prospective Trial to Evaluate Infusion-Related Reactions of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis; Substudy of ESEMBLE (NCT03085810)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 03 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Jul 2024 Final results from full cohort of patients (n=745) from ENSEMBLE PLUS substudy, who received between one and six RDs (Interim clinical cut-off date: 4 Mar 2022) published in the Journal of Neurology
27 Apr 2023 Results for Infusion-Related Reactions With Ocrelizumab, presented at the 75th Annual Meeting of the American Academy of Neurology 2023
13 Oct 2021 According to a Roche media release, subgroup analysis from of three studies (SaROD, CHORDS ENSEMBLE PLUS) in Black, African-American, Hispanic and Latino populations treated with a 2 hour OCREVUS infusion are being presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com